WuXi Biologics Included in S&P Global Sustainability Yearbook 2025
Inclusion in Global Yearbook for third consecutive year
Leader in Green CRDMO to drive innovation for a healthier future
SHANGHAI, March 10, 2025 /PRNewswire/ -- WuXi Biologics ('WuXi Bio') (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been included in the S&P Global Sustainability Yearbook 2025 ('Yearbook') for its strong sustainability performance in 2024. The company was ranked top in its industry and received a Top 1% S&P Global Corporate Sustainability Assessment (CSA) Score, marking the third year WuXi Biologics has received this highest level of recognition.
The Yearbook aims to distinguish individual companies — within a range of industries — that have demonstrated strong corporate sustainability, based on their S&P Global 2024 CSA Score. Out of the 7,690 companies assessed in the 2024 CSA, only 780 companies, across 62 industries, were recognized as the top performers and selected for inclusion in Yearbook 2025.
Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee, commented, 'We are very pleased to be once again selected for inclusion in the Yearbook, a reflection of our steadfast dedication to enhancing our sustainability performance. As a global leader in Green CRDMO, we consistently deliver ESG excellence, enable partners worldwide to fulfill ESG commitments, and jointly work with all stakeholders to promote responsible practices throughout the entire value chain.'
In the past couple of years, WuXi Biologics has also been named to the 2023 and 2024 Dow Jones Sustainability Indices (DJSI) for its unremitting efforts and notable achievements in promoting sustainable development. In addition, as a participant of United Nations Global Compact (UNGC) and Pharmaceutical Supply Chain Initiative (PSCI), WuXi Biologics proactively contributes to advocating sustainability, and has earned widespread recognition for its efforts. It was granted an MSCI AAA Rating and EcoVadis Platinum Medal for two consecutive years; included in the UNGC 20 Case Examples of Sustainable Development for 20 Years Collection for its world-leading green biologics solutions; recognized as a Sustainalytics industry and regional ESG top-rated company for five consecutive years; named to the CDP Water Security 'A list' and awarded an 'A-" CDP Climate Change score; selected as a Constituent of the FTSE4Good Index Series; and listed in the Hang Seng ESG 50 Index.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2024, WuXi Biologics is supporting 817 integrated client projects, including 21 in commercial manufacturing (excluding COVID CMO projects).
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to be an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
3 hours ago
- Associated Press
Bitcoin Solaris Presale Projects 4x Gains with Guaranteed $20 Launch Price
TALLINN, Estonia, July 20, 2025 (GLOBE NEWSWIRE) -- Bitcoin Solaris (BTC-S) is stealing the spotlight in the crypto world as more analysts point toward its potential to turn a modest $1,000 into $4,000 at launch. While the market continues throwing out new tokens every week, few bring the combination of strong fundamentals, breakthrough technology, and sheer investor momentum like BTC-S. This is not your typical presale project hoping for a lucky break. It is built to deliver. Why Bitcoin Solaris Is the Standout in 2025 Bitcoin Solaris does not rely on empty promises. Its strength comes from its hybrid Proof-of-Work and Delegated Proof-of-Stake consensus, delivering lightning-fast speeds while maintaining security at scale. This dual-consensus architecture brings scalability and decentralization together in a way few projects achieve. Through the exciting release of the upcoming Solaris Nova App, Bitcoin Solaris takes mining mainstream. Mobile, desktop, and browser mining means users can participate without expensive rigs or technical headaches. Influencers Are Highlighting BTC-S Potential Influencers and crypto reviewers are spotlighting Bitcoin Solaris as one of the smartest plays this cycle. This Time It's Not Just a Boom It's the Rise of Bitcoin Solaris Presale Momentum Shows No Signs of Slowing Bitcoin Solaris is moving fast through Phase 12 of its presale. With just around 2 weeks left before launch on July 31, 2025, investor interest keeps rising. Over 14,200 unique investors have already joined. More than $6.6M has been raised, making this one of the most explosive presales of the year. Wallets like Trust Wallet and Metamask are recommended for receiving tokens on launch day. BTC-S makes it clear these wallets are for delivery, not presale purchasing. Secure your allocation through Bitcoin Solaris. Mining for Everyone Made Simple Bitcoin Solaris is rewriting the rules on mining with the upcoming Solaris Nova App. Forget expensive equipment and complex setups. Users can calculate their mining potential using the BTC-S calculator. Sustainable Tokenomics for Long-Term Value Bitcoin Solaris ensures a balanced distribution model focused on growth and sustainability. More details are available at the BTC-S Tokenomics. This structure guarantees BTC-S stays decentralized and in the hands of participants who build its future. Final Thoughts: BTC-S Is Built to Deliver Bitcoin Solaris is not just another crypto presale. It is an ecosystem built for scale, accessibility, and long-term adoption. With its dual-consensus model, mobile-first mining, and tokenomics designed for sustainability, BTC-S is positioned to turn small investments into substantial returns. The $20 launch price is around the corner, and this presale window will not last much longer. For more information on Bitcoin Solaris: Media Contact: Xander Levine [email protected] Press Kit: Available upon request Disclaimer:This content is provided by Bitcoin Solaris. The statements, views, and opinions expressed in this content are solely those of the content provider and do not necessarily reflect the views of this media platform or its publisher. We do not endorse, verify, or guarantee the accuracy, completeness, or reliability of any information do not guarantee any claims, statements, or promises made in this content is for informational purposes only and should not be considered financial, investment, or trading advice. Investing in crypto and mining-related opportunities involves significant risks, including the potential loss of is possible to lose all your capital. These products may not be suitable for everyone, and you should ensure that you understand the risks involved. Seek independent advice if necessary. Speculate only with funds that you can afford to are strongly encouraged to conduct their own research and consult with a qualified financial advisor before making any investment decisions. However, due to the inherently speculative nature of the blockchain sector—including cryptocurrency, NFTs, and mining—complete accuracy cannot always be guaranteed. Neither the media platform nor the publisher shall be held responsible for any fraudulent activities, misrepresentations, or financial losses arising from the content of this press the event of any legal claims or charges against this article, we accept no liability or responsibility. GlobeNewswire does not endorse any content on this page. Legal Disclaimer: This media platform provides the content of this article on an 'as-is' basis, without any warranties or representations of any kind, express or implied. We assume no responsibility for any inaccuracies, errors, or omissions. We do not assume any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information presented herein. Any concerns, complaints, or copyright issues related to this article should be directed to the content provider mentioned above. Photos accompanying this announcement are available at
Yahoo
8 hours ago
- Yahoo
Stellantis (STLA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the latest close session, Stellantis (STLA) was down 2.23% at $9.20. The stock trailed the S&P 500, which registered a daily loss of 0.01%. Elsewhere, the Dow lost 0.32%, while the tech-heavy Nasdaq added 0.05%. The automaker's shares have seen a decrease of 1.47% over the last month, not keeping up with the Auto-Tires-Trucks sector's gain of 3.5% and the S&P 500's gain of 5.37%. The upcoming earnings release of Stellantis will be of great interest to investors. The company's earnings report is expected on July 29, 2025. For the annual period, the Zacks Consensus Estimates anticipate earnings of $1.6 per share and a revenue of $180.52 billion, signifying shifts of -40.3% and -11.99%, respectively, from the last year. Investors might also notice recent changes to analyst estimates for Stellantis. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 18.71% lower within the past month. At present, Stellantis boasts a Zacks Rank of #4 (Sell). Looking at its valuation, Stellantis is holding a Forward P/E ratio of 5.9. This represents a discount compared to its industry average Forward P/E of 9.75. It's also important to note that STLA currently trades at a PEG ratio of 0.43. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Automotive - Foreign industry currently had an average PEG ratio of 1.06 as of yesterday's close. The Automotive - Foreign industry is part of the Auto-Tires-Trucks sector. At present, this industry carries a Zacks Industry Rank of 228, placing it within the bottom 8% of over 250 industries. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Ensure to harness to stay updated with all these stock-shifting metrics, among others, in the next trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Stellantis N.V. (STLA) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11 hours ago
- Yahoo
Truist Starts Coverage of Ambac Financial Group (AMBC) Stock with a Buy
Ambac Financial Group, Inc. (NYSE:AMBC) is one of the Truist analyst Mark Hughes initiated coverage of the company's stock with a 'Buy' rating and a price objective of $10, as reported by The Fly. As per the firm, Ambac Financial Group, Inc. (NYSE:AMBC) is a rapidly emerging player in the attractive managing general agent brokerage market. The firm's analyst noted that the company now has the resources to grow its insurance distribution operation, while the sales of its legacy business remain on track for H2 2025. An executive signing a contract to symbolize the financial guarantees the company provides. Ambac Financial Group, Inc. (NYSE:AMBC)'s P&C business saw a strong start to the year, with premium production rising 70% to $318 million and revenue increasing 27% to $63 million in Q1 2025, both on a YoY basis, aided by its acquisition of Beat. Ambac Financial Group, Inc. (NYSE:AMBC)'s increasingly diversified portfolio focuses on long-term growth and withstanding market cyclicality. Ambac Financial Group, Inc. (NYSE:AMBC) has announced the extension from July 3, 2025, to December 31, 2025, of the term of the stock purchase agreement related to the sale of its legacy financial guarantee businesses. Ambac Financial Group, Inc. (NYSE:AMBC)'s top management believes that this transaction is the capstone to its transformation into a pure-play specialty P&C insurance platform. Third Avenue Management, an investment management company based in New York City, released its Q4 2024 investor letter. Here is what the fund said: 'The Fund initiated two new positions during the quarter, OceanFirst Financial ('OCFC') and Ambac Financial Group, Inc. (NYSE:AMBC). Ambac Financial Group, Inc. (NYSE:AMBC) operates as a financial services holding company. While we acknowledge the potential of AMBC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey.
